AOD-9604 vs 5-Amino-1MQ
AOD-9604 is a synthetic hexadecapeptide corresponding to the C-terminal lipolytic domain of human growth hormone, usually written as hGH fragment 176-191. 5-Amino-1MQ is not a peptide at all: it is a small-molecule quinolinium compound that inhibits nicotinamide N-methyltransferase, the enzyme that methylates nicotinamide and thereby consumes S-adenosylmethionine and diverts nicotinamide away from NAD+ salvage. The two are set side by side almost exclusively because both are marketed for fat loss, and the vendor pages that pair them assert confident differences without citing anything that examined the pair. No published study has compared them. Searches of PubMed and of Europe PMC, including full-text searching rather than title and abstract alone, returned no record that names both compounds in any capacity: no comparative experiment, no shared review, no analytical method covering both. Everything below is therefore assembled from two separate literatures built in different fields, on different molecular classes, with different endpoints and different degrees of maturity.
No study has compared them directly.
Everything below is drawn from separate studies that used different models, endpoints and species. That is a real limit on what can be concluded, not a formality.
No published study has administered, assayed or otherwise tested AOD-9604 and 5-Amino-1MQ within the same design, and no publication appears to name both. PubMed searches combining the peptide's synonyms (AOD9604, AOD-9604, hGH fragment 176-191) with the inhibitor's synonyms (5-amino-1MQ, 5-amino-1-methylquinolinium, 5A1MQ, nicotinamide N-methyltransferase inhibitor) returned nothing, and the same combinations run against Europe PMC full text returned nothing. The two literatures do not intersect even at the level of a citation: the AOD-9604 record sits in growth hormone pharmacology, obesity drug development and anti-doping analytical chemistry, while the 5-Amino-1MQ record sits in NNMT enzymology, medicinal chemistry and rodent metabolic physiology. Any comparison between them is indirect, drawn from studies that used different species, different models, different outcome measures and different decades of methodology, which limits what can be said about their relative activity to almost nothing.
Side by side.
| AOD-9604 | 5-Amino-1MQ | |
|---|---|---|
| Evidence maturity | Early clinical | Preclinical only |
| Studies cited here | 17 | 15 |
| Published 2023 or later | 4 | 8 |
| Newest paper | 2026 | 2026 |
| Molecular class and origin | A synthetic 16-amino-acid peptide reproducing the C-terminal lipolytic domain of human growth hormone (Tyr-hGH 177-191). The parent sequence is endogenous, so the fragment corresponds to part of a hormone the body already produces. | A synthetic small molecule, 5-amino-1-methylquinolinium, with no peptide bond and no endogenous counterpart. It was developed as a cell-permeable enzyme inhibitor rather than as an analogue of any human signalling molecule. |
| Mechanism as described in the literature | Rodent work attributed increased lipolysis, reduced lipogenesis and increased fat oxidation to the fragment, with binding experiments indicating no interaction with the growth hormone receptor and pooled human data showing no elevation of IGF-1. Effects persisted in beta3-adrenergic receptor knock-out mice, indicating the action was not mediated directly through that receptor. | Inhibition of nicotinamide N-methyltransferase, which reduces conversion of nicotinamide to 1-methylnicotinamide, preserves S-adenosylmethionine and increases NAD+ availability in adipose tissue and skeletal muscle. Adipose polyamine flux and energy expenditure were the mechanisms invoked in the original knockdown work that made the enzyme a metabolic target. |
| Size of the evidence base | Seventeen verified studies in this library, spanning 1993 to 2026. Primary experimental work on the compound itself is concentrated between 1993 and 2015; the records published since are narrative reviews and analytical chemistry rather than new pharmacology. | Fifteen verified studies in this library, spanning 2014 to 2026, and the primary research is still active, with rodent, enzymology and medicinal-chemistry reports appearing through 2025 and a translational review in 2026. |
| Best-characterised finding | Reduction of body-weight gain in genetically obese and diet-induced obese rodents alongside increased fat oxidation, reported by the same Melbourne-based group across several papers between 2000 and 2001, with the effect separated from growth hormone receptor binding and from adverse effects on insulin sensitivity. | Reduction of body weight and adiposity in diet-induced obese mice without a reduction in food intake, first with selective membrane-permeable quinolinium inhibitors in 2018 and reproduced with 5-amino-1MQ specifically in 2024, where treatment also improved glucose tolerance and liver histopathology. |
| Human data | Present but limited. A 2013 pooled analysis covering six randomised, double-blind, placebo-controlled trials reported safety and tolerability outcomes, absence of an IGF-1 effect and no negative effect on oral glucose tolerance. No efficacy trial has appeared as a standalone peer-reviewed report, so body-composition outcomes in humans have not been independently published. | None. No human clinical trial of 5-Amino-1MQ has been reported in the peer-reviewed literature, and human pharmacokinetics, oral bioavailability and safety are uncharacterised. No biomarker-controlled human study has confirmed target engagement. |
| Safety signals reported | The pooled human analysis described tolerability as indistinguishable from placebo, with no anti-AOD9604 antibodies detected in the patients selected for antibody assay. A separate non-clinical package reported no genotoxic activity across Ames, chromosomal aberration and micronucleus assays and no general safety concern on chronic oral administration in rats and cynomolgus monkeys. | No human safety data of any kind exist. The unresolved questions raised in the preclinical literature concern the long-term consequences of sustained enzyme inhibition for methylation potential, polyamine metabolism and tumour biology, since nicotinamide N-methyltransferase is also implicated in cancer-associated fibroblast biology. |
| Regulatory and anti-doping status | No approved medicine in any jurisdiction. It is listed by the World Anti-Doping Agency among growth hormone analogues and fragments prohibited at all times, and a substantial part of the recent literature consists of urine and blood detection methods, metabolite identification and confirmation of the peptide in seized unlabelled preparations. | No approved medicine in any jurisdiction, and no nicotinamide N-methyltransferase inhibitor has reached approval. It does not appear in the anti-doping analytical literature located for this comparison, so no validated detection method or regulatory listing was identified. |
| Basis of most marketing claims | Extrapolation from rodent lipolysis data and from an unpublished obesity trial programme to human body-composition outcomes that the published record does not contain. The published human data address safety and tolerability, not weight loss. | Extrapolation from mouse diet-induced obesity and aged-muscle experiments, and from the wider NNMT target literature, to human fat loss and muscle function outcomes for which no human study exists at all. |
And what it does not.
The honest summary is that these two compounds have never been examined together, and the published record supplies no basis for ranking them. What the separate literatures support is asymmetric rather than contradictory. AOD-9604 has the older and more clinically advanced file: rodent pharmacology reaching back to 1993, a pooled safety and tolerability analysis drawn from six placebo-controlled human trials, and a non-clinical toxicology package. What it does not have is a published efficacy trial, so the human weight-loss claim rests on data that were never reported in an indexed journal. 5-Amino-1MQ has the more active and more mechanistically detailed file, with reproducible rodent obesity and aged-muscle findings and independent pharmacological confirmation of the enzyme target, but it has no human data whatsoever, and the long-term consequences of sustained methylation-pathway inhibition are unresolved. One compound has human safety without human efficacy; the other has neither. Neither has a controlled human trial demonstrating fat loss.
Common questions.
- Has any published study tested AOD-9604 and 5-Amino-1MQ in the same experiment?
No. Searches of PubMed using the peptide's synonyms alongside the inhibitor's synonyms returned no records, and the same searches run against Europe PMC full text, which indexes the body of open-access papers rather than only titles and abstracts, also returned nothing. No comparative experiment, shared review or combined analytical method appears to exist. The two literatures are built in different fields and do not cite one another, so every comparison circulating in vendor material is an inference rather than a reported result.
- Is 5-Amino-1MQ a peptide?
It is not. 5-Amino-1MQ is 5-amino-1-methylquinolinium, a small-molecule quinolinium salt with a molecular weight of roughly 159 g/mol and no amino acid residues. It is grouped with peptides in retail catalogues because of how it is sold rather than because of what it is. AOD-9604, by contrast, is a genuine 16-residue peptide of about 1815 g/mol reproducing part of the human growth hormone sequence. The two belong to different chemical classes and are handled differently in the analytical literature.
- Which of the two has been given to humans in a controlled trial?
Only AOD-9604. A 2013 report pooled safety and tolerability data from six randomised, double-blind, placebo-controlled studies, including obese adult cohorts, and reported no effect on serum IGF-1 and no negative effect on carbohydrate metabolism on oral glucose tolerance testing. No corresponding efficacy publication exists. For 5-Amino-1MQ the peer-reviewed literature contains no clinical trial of any phase, and its human pharmacokinetics and safety profile are uncharacterised.
- Do the two act on the same biological pathway?
No overlap has been described. The AOD-9604 literature concerns adipocyte lipolysis and lipogenesis downstream of a growth hormone domain, with the reported effects explicitly separated from growth hormone receptor binding and from IGF-1 elevation. The 5-Amino-1MQ literature concerns an enzyme in nicotinamide handling, with downstream consequences for NAD+ availability, S-adenosylmethionine and polyamine flux. No published work has proposed, let alone tested, a shared mechanism or an interaction between them.
- Why does so much recent AOD-9604 literature come from anti-doping laboratories?
Because the compound is prohibited in sport and appears in unregulated supply, which makes its detection an analytical problem worth publishing on. The recent record includes a validated urinary detection method with identified metabolites, confirmation that the peptide does not interfere with the growth hormone isoform immunoassay used in doping control, and a case report characterising it in preparations seized by national authorities. These are detection and identification studies; none of them generates efficacy data.
For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition. Nothing on this page is medical advice, and no comparison here should be read as a recommendation of either compound.